Question 1

What are the most cited papers from Gesynta Pharma (Sweden)?

Accepted Answer

The most cited paper from Gesynta Pharma (Sweden) is "THE COURSE OF ESTABLISHED ANKYLOSING SPONDYLITIS AND THE EFFECTS OF SULPHASALAZTh OVER 3 YEARS" (John Kirwan, Alison Edwards, B. Huitfeldt et al., 1993), with 74 citations. Next come "Biological characterization of new inhibitors of microsomal PGE synthase‐1 in preclinical models of inflammation and vascular tone" (32) and "A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's" (16).

Question 2

Which research topics does Gesynta Pharma (Sweden) publish most on?

Accepted Answer

By volume in 2022-now: Endometriosis Research and Treatment, Chronic Obstructive Pulmonary Disease (COPD) Research, Inflammatory mediators and NSAID effects and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis.

Question 3

Which fields of science does Gesynta Pharma (Sweden) work in?

Accepted Answer

In all years, 58% of research at Gesynta Pharma (Sweden) is in Health Sciences, 23% in Life Sciences. Its largest fields are Medicine (58%), Biochemistry, Genetics and Molecular Biology (15%), Chemistry (12%).

Question 4

Is Gesynta Pharma (Sweden)'s research output growing?

Accepted Answer

Output in 2022-2025 was 94% higher than in 2018-2021.